CNTB CONNECT BIOPHARMA HLDGS LTD

Connect Biopharma to Host a Conference Call Tuesday, October 4 to Discuss Topline Results for the Pivotal Trial in China of Lead Candidate, CBP-201, in Patients with Moderate-to-Severe Atopic Dermatitis

Connect Biopharma to Host a Conference Call Tuesday, October 4 to Discuss Topline Results for the Pivotal Trial in China of Lead Candidate, CBP-201, in Patients with Moderate-to-Severe Atopic Dermatitis

Conference call and webcast to take place at 5:30 a.m. PDT/8:30 a.m. EDT,

tomorrow, Tuesday, October 4

SAN DIEGO and TAICANG, SUZHOU, China, Oct. 03, 2022 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (Nasdaq: CNTB) (Connect Biopharma or the Company), a company developing therapeutics for T cell-driven inflammatory diseases, today announced it will report topline results for its pivotal trial in China of lead candidate, CBP-201, in patients with moderate-to-severe atopic dermatitis (AD). Following the press release, the Company will host a webcast and conference call at 5:30 a.m. PDT to discuss these results.

The news release will be posted to the investor relations section of Connect Biopharma’s website at: .

  • For a listen-only webcast that includes the slide presentation, investors can follow this link: . The replay will be available for 12 months.
  • To participate in the live telephone conference call, follow this link to register in advance:  Upon registering, you will receive a dial-in number and unique PIN to join the conference call.

About Connect Biopharma Holdings Limited

Connect Biopharma is a U.S. and China-based clinical-stage biopharmaceutical company dedicated to improving the lives of patients with inflammatory diseases through the development of therapies derived from T cell research. The Company is building a rich pipeline of proprietary small molecules and antibodies, using functional T cell assays, to screen and discover potent product candidates against validated immune targets. The Company’s lead product candidate, CBP-201, is an antibody designed to target interleukin-4 receptor alpha (IL-4Rα) in development for the treatment of atopic dermatitis and asthma. The Company’s second most advanced product candidate, CBP-307, is a modulator of S1P1 T cell receptor and is in development for the treatment of ulcerative colitis (UC). The Company’s third product candidate, CBP-174, is a peripherally acting antagonist of histamine receptor 3, in development for the treatment of pruritus associated with AD. For more information, please visit:

IR/PR CONTACTS: 

Ina McGuinness

T: +1 (805) 427-1372



 



EN
03/10/2022

Underlying

CNTBCONNECT BIOPHARMA HLDGS LTD

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on CONNECT BIOPHARMA HLDGS LTD

 PRESS RELEASE
Free
CNTB CONNECT BIOPHAR...

Connect Biopharma Reports 2025 Full-Year Financial Results and Provide...

Connect Biopharma Reports 2025 Full-Year Financial Results and Provides Business Update – Released positive topline data from Phase 1 study of IV rademikibart in patients with asthma or COPD – – Results from Phase 3 study of rademikibart in moderate-to-severe AD presented in late-breaking research session at AAD – – Recruitment ongoing for Phase 2 Seabreeze STAT studies for acute exacerbations in asthma and COPD; expect to report topline data from both studies mid-2026 – – Entered into a securities purchase agreement for $20.2 million equity financing extending our cash runway into secon...

March 31, 2026 1 EN
 PRESS RELEASE
Free
CNTB CONNECT BIOPHAR...

Connect Biopharma Announces $20.2 Million Private Placement Financing

Connect Biopharma Announces $20.2 Million Private Placement Financing Funding from new and existing investors extends anticipated cash runway into the second half of 2027 SAN DIEGO, March 30, 2026 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (Nasdaq: CNTB) (“Connect Biopharma,” “Connect” or the “Company”), a clinical-stage biopharmaceutical company focused on transforming care for the treatment of inflammatory diseases, today announced that it has entered into a securities purchase agreement with a select group of institutional accredited investors to sell 6,130,000 shares of ...

March 30, 2026 1 EN
 PRESS RELEASE
Free
CNTB CONNECT BIOPHAR...

Rademikibart Demonstrates Best-in-Class Potential in Phase 3 Atopic De...

Rademikibart Demonstrates Best-in-Class Potential in Phase 3 Atopic Dermatitis Study – Rademikibart achieved rapid, durable efficacy results across all key endpoints through 52 weeks, with near‑maximal responses achieved in ~90% of patients – – Rademikibart was well tolerated with safety comparable to placebo – – Data presented during late-breaking oral presentation at 2026 American Academy of Dermatology Annual Meeting –  – Company to host conference call and webcast today, March 30, 2026 at 8:00 a.m. ET – SAN DIEGO, March 30, 2026 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limit...

March 30, 2026 1 EN
 PRESS RELEASE
Free
CNTB CONNECT BIOPHAR...

Connect Biopharma Announces Positive Topline Data from its Phase 1 Stu...

Connect Biopharma Announces Positive Topline Data from its Phase 1 Study of Intravenous (IV) Rademikibart in Patients with Asthma or COPD – Rademikibart administered as a single 300 mg 2-minute IV push to asthma and chronic obstructive pulmonary disease (COPD) patients produced rapid improvement in FEV1 with many patients experiencing improvements in airway function of ≥200 mL as early as 15 minutes post-dosing – – The rapid improvement in FEV1 demonstrated with IV rademikibart in this study provides clinical confirmation of preclinical observations that rademikibart has a unique benefic...

March 30, 2026 1 EN
 PRESS RELEASE
Free
CNTB CONNECT BIOPHAR...

Results from Phase 3 Study of Rademikibart in Moderate-to-Severe Atopi...

Results from Phase 3 Study of Rademikibart in Moderate-to-Severe Atopic Dermatitis to be Presented in the Late-Breaking Research Session at the 2026 American Academy of Dermatology (AAD) Annual Meeting SAN DIEGO, March 10, 2026 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (Nasdaq: CNTB) (Connect Biopharma, Connect, or the Company), a clinical-stage biopharmaceutical company focused on transforming care for the treatment of inflammatory diseases, today announced that the results of a Phase 3 study of rademikibart in moderate-to-severe atopic dermatitis (AD) conducted by the Compa...

March 10, 2026 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch